Retrospective analysis of the use of osteoporosis medication at the presentation of fragility fractures in a predominantly Hispanic population.
Abstract
Despite the high incidence of osteoporosis, many patients at risk of fragility fractures may not initiate treatment due to concerns about side effects, or cost. We aimed to identify whether the patient population presenting with fragility fractures is receiving prophylactic treatment for osteoporosis within a single academic hospital in the southernmost region of the United States. This region is characterized by a high number of patients from Hispanic/Latino heritage (80%) and reduced access to healthcare services. We conducted a three-year, retrospective cohort study of patients presenting with low impact fractures of the humerus or the shoulder griddle, lower end of radius or ulna and forearm, hip fractures (femoral neck, intertrochanteric/subtrochanteric), the lower end of tibia, medial malleolus, lateral malleolus or lower leg. Male and female subjects of 50 years or older were included. Demographic data and information on medications reported at fracture presentation were extracted from electronic medical records. We found that 42% of the patients were taking at least one medication to prevent osteoporosis. The predominant combination was vitamin D plus calcium and bisphosphonates. If patients taking only vitamin D plus calcium are excluded, 16.7% of the sample took osteoporosis medications at the fragility fracture presentation. The likelihood of taking osteoporosis medication was increased by age and type of health insurance (Medicare/private insurance), and concomitant diagnosis of impaired gait and mobility. The percentage of the patients taking prophylactic medications for osteoporosis at the time of a fragility fracture was comparable to reported national standards and associated with increased age and health insurance coverage. In a predominantly Hispanic/Latino patient population living in a medically underserved region, there is substantial recognition and prevention strategies for osteoporosis.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An updated analysis of opioids increasing the risk of fractures
- Osteoporosis Genetic Risk Prediction Using Bone Mineral Density Polygenic Scores in Japanese: TMM CommCohort Study
Yayoi Otsuka‐Yamasaki, Yoichi Sutoh, … Atsushi Shimizu·Journal of Human GeneticsPeer-reviewed·Sep 9, 2026
- Differences in Characteristics of Medicare Patients Treated by Ophthalmologists and Optometrists
Darby D. Miller, Michael W. Stewart, … Aaron Lee·PLoS ONEPeer-reviewed·Sep 14, 2020
- Multi-omics analyses of drug repurposing reveal Acebutolol and Amiloride for osteoporosis treatment
Danyang Liu, Jonathan Greenbaum, … Hong‐Wen Deng·bioRxiv·May 3, 2022
- Modeling osteoporosis to design and optimize pharmacologic therapies comprising multiple drug types
D. J. Jörg, D. H. Fuertinger, … P. Kotanko·bioRxiv·Dec 17, 2021
- Assessing Disease Experience across the Life Span for Individuals with Osteogenesis Imperfecta: Challenges and Opportunities for Patient-Reported Outcomes (PROs) Measurement
Laura Lowe Tosi, Marianne Floor, … Jeffrey P. Krischer·Orphanet Journal of Rare DiseasesPeer-reviewed·Jan 29, 2019